TABLE 3.
| Attributes | Larotrectinib | Entrectinib |
|---|---|---|
| Indication | Adults and children | Adults and children 12 years and older |
| Dosing | 100 mg twice a day for adults; 100 mg/m2 twice a day (to a maximum of 100 mg per dose) for children | 600 mg once a day for adults; 300 mg/m2 once a day for children |
| Formulation | Capsules and liquid | Capsules |
| Response rate | ||
| ORR | 75% | 57% |
| CR | 22% | 7.4% |
| PR | 53% | 50% |
| All-grade AEs in ≥ 20% of patients for either drug | ||
| Fatigue | 37% | 48% |
| Dizziness | 28% | 38% |
| Nausea | 29% | 34% |
| Dyspnea | 18% | 30% |
| Myalgia | 14% | 28% |
| Increased weight | 15% | 25% |
| Arthralgia | 14% | 21% |
| Vision disorders | NR | 21% |
| Cough | 26% | 24% |
| Vomiting | 26% | 24% |
| Constipation | 23% | 46% |
| Diarrhea | 22% | 35% |
| Dysgeusia | NR | 44% |
| Edema | 15% | 40% |
| Dysesthesia | NR | 34% |
| Cognitive impairment | NR | 27% |
| Pyrexia | 18% | 21% |
| Warnings | Hepatotoxicity, embryo-fetal toxicity, neurotoxicity | Hepatotoxicity, embryo-fetal toxicity, CNS effects, congestive heart failure, skeletal fractures, hyperuricemia, QT interval prolongation, vision disorders |
| AE-related fatalities | None | Dyspnea (0.6%), pneumonia (0.6%), sepsis (0.6%), completed suicide (0.3%), large intestine perforation (0.3%), tumor lysis syndrome (0.3%) |
AE, adverse event; CNS, central nervous system; CR, complete response; NR, not reported; ORR, objective response rate; PR, partial response.
a
For illustrative purposes only; cross-trial comparisons must not be made.